You are here

UCB

UCB

With its headquarters in Belgium, UCB is active around the world. The organisation’s research and development focuses on medication for patients with serious neurological and immunological diseases such as epilepsy, Parkinson’s disease, rheumatoid arthritis and osteoporosis. 
 
Through its continuous development of holistic, therapeutic treatments that better respond to medical needs, UCB is recognised as the partner of preference for patients. Our innovative solutions in eHealth play a crucial role. 
Contact us: 
Erik Janssen, VP Innovation Neurology & Peter Dedeken, Head of EU Medical Managers Seizure Freedom
Tel: 
02 559 94 32
Website: 
A BlueHealth Antwerp partner
 
Peter Dedeken: ‘At the first meeting with BlueHealth Antwerp, it became apparent that we were on the same mission. BlueHealth Antwerp put the emphasis on digital applications that benefit the patient. That is the centre of everything we do at UCB. Besides medication, how can we make a difference for patients? In other words, how can we make an impact on patients’ quality of life that they will genuinely feel?’
 
Erik Janssen: ‘The core business for UCB is and remains the research and development of medicines. To make a genuine difference for patients, we believe in a holistic approach in which all players work together. If you ask me, eHealth applications will play an important role in this in the future. With digital innovation, we can take a giant leap towards better patient-centric healthcare.’ 
 
Expertise
 
Peter Dedeken: ‘UCB is active in more than 70 countries. This allows us to give startups access to an enormous network of research and academic partners. Furthermore, we have years of expert experience in research, development, product approval, reimbursement and commercialisation. Our knowledge is especially strong in neurological and immunological diseases. Through it, startups share in our credibility; credibility that is based on years of experience and that helps them to navigate their way in an increasingly complex world.’
 
Future
 
Erik Janssen: ‘As an important biopharmaceutical player, we think it is part of our role to contribute to the constant innovation of healthcare. BlueHealth Antwerp gives a clear signal that there is room for well-informed ideas and innovative applications. We are glad to join them in this movement.
 
‘For our own operations, it is of course extremely interesting to work together with such driven and talented entrepreneurs. We look forward enormously to the cross-pollination and interesting collaboration that has come into existence through BlueHealth Antwerp.’